Serious adverse events: intussusception · children
RotaTeq showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
3 findings from 1 review
RR 0.69 [0.35, 1.38]
9 studies · 73925 participants
Low
RR 5.01 [0.24, 104.29]
2 studies · 4082 participants
Very low
RR 0.33 [0.01, 8.16]
2 studies · 7488 participants
Low
Serious adverse events: intussusception · children
Rotasiil showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: intussusception · children
It is very uncertain whether rotavac changes serious adverse events: intussusception compared with placebo (very low certainty).
1 finding from 1 review
adverse events: grade 1 to 2 dermatitis · healthy men
Selenium leads to higher adverse events: grade 1 to 2 dermatitis compared with placebo (high certainty).
1 finding from 1 review
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Alopecia, skin toxicity, hot flush, drowsiness, sneezing, hiccupping, dizziness and fatigue reported narratively or only for the amifostine group; insufficient evidence of a difference
Studies not reported
GRADE not reported
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
No evidence of a difference for any other adverse event (nausea, vomiting, chilling, headache, lacrimation, dysphasia, weakness, nervousness, rhinitis, blurred vision, urinary frequency, dizziness, palpitation, skin…
Studies not reported
GRADE not reported
Intervention not reported
Adverse events Number of adverse events · patients with essential tremor
It is very uncertain whether the intervention changes adverse events Number of adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Total adverse events Incidence of event · people following primary uncemented THA
It is very uncertain whether the intervention changes total adverse events Incidence of event (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events (AEs) (grade 3 or 4) ‐ Network included 19 pairwise comparisons ‐ Mean risk with SUN across trials3 in this network: 70.6% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
1 finding from 1 review
Intervention not reported
Serious adverse events (SAEs) ‐ Network included 31 pairwise comparisons ‐ Mean risk with SUN across trials3 included in this network: 40.7% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention showed no clear difference in serious adverse events (SAEs) ‐ Network included 31 pairwise… (moderate certainty).
1 finding from 1 review
Adverse events 12 months postintervention · people who smoke
Heated tobacco use showed no clear difference in adverse events – measured by self‐report compared with cigarette smoking (low certainty).
1 finding from 1 review
Adverse events 12 months postintervention · people who smoke
It is very uncertain whether heated tobacco use changes adverse events – measured by self‐report compared with snus use (very low certainty).
1 finding from 1 review
Adverse events 12 months postintervention · people who smoke
It is very uncertain whether heated tobacco use changes adverse events – measured by self‐report compared with abstinence from tobacco (very low certainty).
1 finding from 1 review
Adverse events ‐ malignancy at 36 months · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ malignancy at 36 months compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
Participants with serious adverse events · people who have been exposed to SARS‐CoV‐2
1 finding from 1 review
Participants with serious adverse events · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) showed no clear difference in participants with serious adverse events compared with standard care or placebo (low certainty).
1 finding from 1 review
Serious adverse events at up to 4.5‐year · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in serious adverse events at up to 4.5‐year compared with quadrivalent HPV vaccine (low certainty).
1 finding from 1 review
Intervention not reported
Total adverse events Incidence of events · people following primary uncemented THA
1 finding from 1 review
Withdrawals due to adverse events · adults with panic disorder
TCA showed no clear difference in number of dropouts due to adverse events compared with MAOI (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with panic disorder
SSRIs showed no clear difference in number of dropouts due to adverse events compared with MAOIs (low certainty).
1 finding from 1 review